DZ3377A1 - Azaindoles - Google Patents

Azaindoles

Info

Publication number
DZ3377A1
DZ3377A1 DZ003377A DZ003377A DZ3377A1 DZ 3377 A1 DZ3377 A1 DZ 3377A1 DZ 003377 A DZ003377 A DZ 003377A DZ 003377 A DZ003377 A DZ 003377A DZ 3377 A1 DZ3377 A1 DZ 3377A1
Authority
DZ
Algeria
Prior art keywords
azaindoles
Prior art date
Application number
DZ003377A
Other languages
English (en)
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Justine Yeun Quai Lai
Andrew David Morley
Shelley Amendola
Stephanie Deprets
Chris Edlin
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DZ3377A1 publication Critical patent/DZ3377A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
DZ003377A 1999-12-24 2000-12-27 Azaindoles DZ3377A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930698.7A GB9930698D0 (en) 1999-12-24 1999-12-24 Chemical compounds
US21581800P 2000-07-05 2000-07-05
PCT/GB2000/004993 WO2001047922A2 (fr) 1999-12-24 2000-12-27 Azaindoles

Publications (1)

Publication Number Publication Date
DZ3377A1 true DZ3377A1 (fr) 2001-07-05

Family

ID=26316153

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003377A DZ3377A1 (fr) 1999-12-24 2000-12-27 Azaindoles

Country Status (27)

Country Link
US (2) US6770643B2 (fr)
EP (2) EP1263759B1 (fr)
JP (1) JP5436507B2 (fr)
KR (2) KR100755622B1 (fr)
CN (2) CN1615873A (fr)
AP (2) AP1587A (fr)
AU (1) AU777717B2 (fr)
BG (2) BG66066B1 (fr)
BR (1) BR0017038A (fr)
CA (2) CA2699568C (fr)
CY (1) CY1110951T1 (fr)
CZ (2) CZ301751B6 (fr)
DZ (1) DZ3377A1 (fr)
EA (1) EA005212B1 (fr)
EE (1) EE05180B1 (fr)
HK (1) HK1050191B (fr)
HR (1) HRP20020547B1 (fr)
HU (1) HUP0203895A3 (fr)
IL (3) IL150388A0 (fr)
MA (1) MA26857A1 (fr)
MX (1) MXPA02006338A (fr)
NO (2) NO323766B1 (fr)
NZ (1) NZ519121A (fr)
OA (1) OA12514A (fr)
PL (1) PL209572B1 (fr)
SK (2) SK287882B6 (fr)
WO (1) WO2001047922A2 (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2679459B2 (ja) 1991-08-02 1997-11-19 王子製紙株式会社 感熱記録体
WO2001047922A2 (fr) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
EP1363705B9 (fr) * 2001-02-02 2012-11-07 Bristol-Myers Squibb Company Composition et activite antivirale de derives de piperazine azaindoleoxoacetique substitues
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) * 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
WO2003082869A1 (fr) * 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n
DE60316542T2 (de) * 2002-03-28 2008-07-03 Eisai R&D Management Co., Ltd. 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
WO2003087087A2 (fr) * 2002-04-09 2003-10-23 Astex Technology Limited Composes pharmaceutiques
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1388541A1 (fr) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
EP1545515A1 (fr) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2295433A3 (fr) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. Inhibiteurs de JNK
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
CA2532403A1 (fr) 2003-07-17 2005-02-03 James Arnold Composes ayant une activite sur des ppar
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP1694686A1 (fr) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Inhibiteurs de kinase
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
WO2006023931A2 (fr) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Inhibiteurs de kinase
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP2008525355A (ja) * 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
EP2354140A1 (fr) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines en tant qu'inhibiteurs de kinase
WO2007007919A2 (fr) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Nouveaux composes
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US8076365B2 (en) * 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2621261C (fr) 2005-09-22 2014-05-20 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007067537A1 (fr) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EA200870117A1 (ru) * 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
WO2007084667A2 (fr) * 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Inhibiteurs de kinase heterobicycliques fusionnes
WO2007136790A2 (fr) * 2006-05-18 2007-11-29 Mannkind Corporation Inhibiteurs de kinases intracellulaires
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
WO2008014249A2 (fr) * 2006-07-24 2008-01-31 Sanofi-Aventis Préparation améliorée de composés d'azaindole
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
CA2673038C (fr) * 2006-12-22 2015-12-15 Incyte Corporation Composes heteroaryls tricycliques substitues comme inhibiteurs de kinase janus
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
UA104849C2 (uk) * 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
ES2372908T3 (es) 2008-02-25 2012-01-27 F. Hoffmann-La Roche Ag Inhibidores de la pirrolopirazina quinasa.
WO2009106444A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
JP5368485B2 (ja) * 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
CA2712507A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
CN101945877B (zh) * 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
MX2010008308A (es) * 2008-03-10 2010-08-11 Sanofi Aventis Tratamiento para trastornos relacionados con los ojos.
HUE029767T2 (en) * 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
EP2274288A2 (fr) * 2008-04-24 2011-01-19 Incyte Corporation Composés macrocycliques et leur utilisation à titre d'inhibiteurs de kinase
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (fr) * 2008-10-21 2010-04-29 Syngenta Participations Ag Dérivés de diazaindole et leur emploi en tant que fongicides
WO2010085597A1 (fr) 2009-01-23 2010-07-29 Incyte Corporation Composés macrocycliques et leur utilisation en tant qu'inhibiteurs des kinases
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
SI2432472T1 (sl) * 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
ES2483594T3 (es) * 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
US8816085B2 (en) 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EP2338890A1 (fr) 2009-12-22 2011-06-29 Bayer CropScience AG Dérivés de 4,7-diazaindole et leur utilisation en tant que fongicides
JP5858434B2 (ja) * 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
WO2011109932A1 (fr) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Nouveau procédé pour la fabrication de 7-azaindoles 5-halogénés
EP3354652B1 (fr) 2010-03-10 2020-05-06 Incyte Holdings Corporation Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
EP2571881A1 (fr) * 2010-05-20 2013-03-27 F.Hoffmann-La Roche Ag Dérivés de pyrrolopyrazine comme inhibiteurs de syk et jak
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
EP2706853B1 (fr) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines en tant qu'inhibiteurs de syk
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
CA2834062A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridylaminopyridines en tant qu'inhibiteurs de syk
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP2741747A1 (fr) 2011-08-10 2014-06-18 Novartis Pharma AG Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763975B1 (fr) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
CA2863717C (fr) * 2012-02-21 2021-09-28 Lars Burgdorf Derives de furopyridine
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2863913B1 (fr) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
EP2863914B1 (fr) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP2863915B1 (fr) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
EP2863916B1 (fr) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
US9796708B2 (en) 2013-03-14 2017-10-24 Abbvie Inc. Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
WO2014151444A1 (fr) * 2013-03-14 2014-09-25 Abbvie Inc. Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase
DK2970265T3 (en) * 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP6709786B2 (ja) 2014-12-11 2020-06-17 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
TW201904577A (zh) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
WO2020132384A1 (fr) 2018-12-21 2020-06-25 Celgene Corporation Inhibiteurs thiénopyridine de ripk2
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102818206B1 (ko) * 2021-07-12 2025-06-11 한양대학교 에리카산학협력단 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
US5202108A (en) * 1990-10-12 1993-04-13 Analytical Development Corporation Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
JPH10510510A (ja) * 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
WO1998006703A1 (fr) 1996-08-14 1998-02-19 Warner-Lambert Company Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1
US5783969A (en) 1996-09-04 1998-07-21 Motorola, Inc. Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
KR20000057137A (ko) * 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
GB9708235D0 (en) * 1997-04-23 1997-06-11 Ciba Geigy Ag Organic compounds
WO1998047899A1 (fr) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
CN1264381A (zh) * 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
BR9812944A (pt) * 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
JP2002510631A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
WO1999051595A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
AU3117899A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2326143A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051233A1 (fr) * 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
EP1077967B1 (fr) 1998-05-12 2002-12-04 Wyeth Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
ATE482945T1 (de) 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) * 1998-07-10 2000-07-12 Pfizer Products Inc. 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
ES2253930T3 (es) * 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-aminopirrolopirimidinas como inhibidores de quinasa.
AU3126900A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Products Inc. Alpha-substitution of unprotected beta-amino ester compounds
DE60007310D1 (de) 1999-06-04 2004-01-29 Elan Pharma Int Ltd Zusammensetzungen und methoden zur verhinderung des zelltods
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de) 1999-09-14 2001-03-15 Wilke Heinrich Hewi Gmbh Verriegelungsvorrichtung
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001047922A2 (fr) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
EP1259236A4 (fr) 2000-02-25 2004-11-03 Merck & Co Inc Inhibiteurs de tyrosine-kinase
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
WO2001082930A1 (fr) * 2000-05-03 2001-11-08 Tularik Inc. Agents microbiens a base de pyrazole
JP2004503553A (ja) 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ６，５−縮合二環式複素環
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
BG66066B1 (bg) 2011-01-31
NZ519121A (en) 2004-05-28
BG110623A (bg) 2010-07-30
KR20020062663A (ko) 2002-07-26
CA2395593A1 (fr) 2001-07-05
CZ20022207A3 (cs) 2002-11-13
KR100755622B1 (ko) 2007-09-04
EP1263759A2 (fr) 2002-12-11
HUP0203895A3 (en) 2004-09-28
EP1990343A3 (fr) 2008-12-10
CZ301750B6 (cs) 2010-06-09
NO20023032L (no) 2002-06-21
JP2012031181A (ja) 2012-02-16
KR100910488B1 (ko) 2009-08-04
BG66176B1 (bg) 2011-11-30
PL209572B1 (pl) 2011-09-30
CA2699568C (fr) 2013-03-12
HUP0203895A2 (hu) 2003-02-28
NO330747B1 (no) 2011-07-04
WO2001047922A3 (fr) 2002-01-17
NO20023032D0 (no) 2002-06-21
SK9012002A3 (en) 2003-04-01
AU2209401A (en) 2001-07-09
BG106836A (bg) 2003-04-30
US20040009983A1 (en) 2004-01-15
CA2699568A1 (fr) 2001-07-05
CY1110951T1 (el) 2015-06-11
EP1990343A2 (fr) 2008-11-12
PL355819A1 (en) 2004-05-17
BR0017038A (pt) 2003-01-07
AP1587A (en) 2006-03-02
MXPA02006338A (es) 2002-12-13
EP1990343B1 (fr) 2012-04-04
CZ301751B6 (cs) 2010-06-09
SK288019B6 (sk) 2012-11-05
CA2395593C (fr) 2011-08-02
AU777717B2 (en) 2004-10-28
CN1615873A (zh) 2005-05-18
HK1050191A1 (en) 2003-06-13
HRP20020547B1 (hr) 2011-06-30
EA005212B1 (ru) 2004-12-30
HK1050191B (en) 2011-04-29
MA26857A1 (fr) 2004-12-20
AP2002002516A0 (en) 2002-06-30
JP5436507B2 (ja) 2014-03-05
NO20066017L (no) 2002-06-21
OA12514A (en) 2006-05-29
IL193615A0 (en) 2009-05-04
SK287882B6 (sk) 2012-02-03
EA200200707A1 (ru) 2003-02-27
HRP20020547A2 (hr) 2005-10-31
AP2006003492A0 (en) 2006-02-28
WO2001047922A2 (fr) 2001-07-05
IL150388A (en) 2010-11-30
EP1263759B1 (fr) 2010-09-08
US6770643B2 (en) 2004-08-03
CN1413213A (zh) 2003-04-23
US7227020B2 (en) 2007-06-05
KR20070050103A (ko) 2007-05-14
US20040198737A1 (en) 2004-10-07
NO323766B1 (no) 2007-07-02
EE05180B1 (et) 2009-06-15
AP1917A (en) 2008-11-12
CN100379734C (zh) 2008-04-09
EE200200343A (et) 2003-06-16
IL150388A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
DZ3377A1 (fr) Azaindoles
DE50010505D1 (de) Gurtaufrollersystem
DE122007000064I1 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
DE60022893D1 (de) Naphthyridinverbindungen
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE50009570D1 (de) Wechselcorrugator
DE50007953D1 (de) Beleuchtungsanordung
DE50008613D1 (de) Sicherungsring
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50012482D1 (de) Tibiamarknagel
DE50003660D1 (de) Diacylhydrazinderivate
DE50003259D1 (de) Textilie
DE50006013D1 (de) Anschlagpuffer
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole
ATE440824T1 (de) Nitro-sulfobenzamide
DE50009208D1 (de) Hydroxyphenylvinylthiazole